Skip to main content
. 2016 Aug 5;8(9):14343–14358. doi: 10.18632/oncotarget.11102

Figure 7. Targeting EMP3 attenuates.

Figure 7

in vivo tumor growth and prolongs tumor-bearing mice survival. A. EMP3 depletion attenuated subcutaneous tumor growth. n = 6, *P < 0.05, as compared with scramble (Scr) control. B. Western blotting analysis on protein lysates from subcutaneous tumors with or without EMP3 depletion at week 5 after implantation. C. Targeting EMP3 prolongs tumor-bearing mice survival in an orthotopic xenograft model (n = 10). D. EMP3 depletion attenuates in vivo tumor growth in an orthotopic xenograft model. n = 6, *P < 0.05, as compared with scramble (Scr) control. Bars: 1 mm. E. Immunostaining of the intracranial tumors at day 30 after implantation. The tissue sections were incubated with antibodies against indicated antibodies (EMP3, p-Smad2/3 and Ki-67). Diaminobenzidine was used as a chromogen, followed by counterstaining with hematoxylin. Bar, 50 μm. Ki-67, Scr versus shEMP3 (n = 6), P < 0.05. F. EMP3 depletion induces apoptosis in intracranial xenografts. Incidence of apoptosis was determined by TUNEL staining. Bar, 50 μm. *P < 0.05, Scr versus shEMP3.